Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

122results about How to "Potent activity" patented technology

Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells

InactiveUS20060239910A1Improve anti-tumor activityEnhanced antibody-dependent cellular cytotoxicityOrganic active ingredientsNanomedicineDrug specific IgEFolate Receptor Alpha
This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate receptor alpha (FRA) and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to FRA-expressing cells as well as in eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer cells; and methods of treating cancer using the antibodies.
Owner:EISAI INC

Novel chemotherapeutic agents against inflammation and cancer

Novel compounds, their methods of preparation and use in therapies related to cancer and inflammation are provided. Compounds comprise esters of cinnamic acid, vanillic acid and 4-hydroxy cinnamic acid and derivatives and salts thereof. Compounds with novel benzofuran lignan structure as a potent antimitotic agent and inducer of apoptosis are provided. Formulations and methods for treatment of diseases mediated by NF-kappaB are also provided.
Owner:RELIANCE LIFE SCI PVT

Picolinamide derivative and harmful organism control agent comprising said picolinamide derivative as active component

Disclosed are novel compounds useful for the control of harmful organisms, harmful organism control agents using the same, and processes for producing the novel compounds. The useful novel compounds according to the present invention include compounds represented by formula (1). The compounds represented by formula (1) have potent activity against harmful organisms, and do not have phytotoxicity against agricultural and gardening plants, as objects to which the compounds of the present invention are applied for preventive and exterminating purposes, and human beings and beastswherein A represents a bond or an optionally substituted alkylene chain; R1 represents one or more groups, which may be the same or different, selected from the group consisting of a hydrogen atom, alkoxy, and haloalkoxy; R2 represents a hydrogen atom, benzyl, alkyl or alkanoyl, in which the groups other than the hydrogen atom may be substituted; and R3 represents a hydrogen atom, cycloalkyl, cycloalkenyl, aryl or a heterocyclic group, in which the groups other than the hydrogen atom may be substituted, excluding the case where R1 represents a hydrogen atom, A represents a bond or a methylene chain, and R3 represent phenyl or cyclohexyl, and the case where A represents an alkylene chain and R3 represents a hydrogen atom.
Owner:MEIJI SEIKA KAISHA LTD

Compounds with the bicyclo[4.2.1]nonane system for the treatment of flavivridae infections

InactiveUS20040082574A1Potent and selective activityPotent activityBiocideSugar derivativesPestivirusMedicine
The disclosed invention is a bicyclo[4.2.1]nonane and its pharmaceutically acceptable salt or prodrug, and its composition and method of use to treat Flaviviridae (Hepacivirus, Flavivirus, and Pestivirus) infections in a host, including animals, and especially humans.
Owner:PHARMASSET

Benzothiepin derivatives, process for the preparation of the same and uses thereof

InactiveUS6355672B1Potent osteogenesis promoting effectLow toxicityBiocideOrganic chemistryDiseaseHydrogen atom
The invention provides compounds of the formula:wherein the ring A is an optionally substituted benzene ring; R1 is an optionally substituted non-aromatic heterocyclic group; R2 and R3 are independently hydrogen atom or an optionally substituted hydrocarbon group; n is an integer of 0-3; or salts thereof, which are useful as medicines having an osteogenesis promoting effect and chondrogensis promoting effect.The present invention relates to an amine compound having an excellent effect of inhibiting production and / or secretion of amyloid-b protein, a production and use thereof. Especially, it is effective for preventing and / or treating, for example, neurodegenerative diseases, amyloid angiopathy, neurological disorders caused by cerebrovascular disorders, and so forth.
Owner:TAKEDA PHARMA CO LTD

Derivatives of (-)-venlafaxine and methods of preparing and using the same

InactiveUS6342533B1Potent activityReducing and avoiding adverse effectBiocideNervous disorderDementiaWeight gain
Methods of preparing, and compositions comprising, derivatives of (-)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.
Owner:SUNOVION PHARMA INC

O-desmethylvenlafaxine and methods of preparing and using the same

Methods of preparing, and compositions comprising, derivatives of venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.
Owner:WYETH LLC

Method of Treating Cancer

InactiveUS20120252840A1Potent activityReduces tumor invasivenessBiocideAnimal repellantsDual inhibitorOcular Melanoma
This invention is directed to the treatment of cancer, particularly ocular melanoma, with a dual inhibitor of MET and VEGF such as Compound 1.
Owner:EXELIXIS INC

Imidazole derivative, process for producing the same, and use

InactiveUS20070004736A1Improve drug efficacyImproved oral absorbabilityBiocideOrganic chemistryCyclic hydrocarbonDivalent
There is provided an imidazole derivative useful as a thrombosis treating agent, which is represented by the formula (I): wherein R represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group, W represents a bond or an optionally substituted divalent linear hydrocarbon group, X represents an optionally substituted divalent hydrocarbon group, Y represents —CO—, —S(O)—, —S(O)2— or a bond, ring A represents an optionally substituted pyrrolidine ring, an optionally substituted piperidine ring or an optionally substituted perhydroazepine ring, Z1 and Z3 independently represent a bond or an optionally substituted divalent linear hydrocarbon group, Z2 represents —N(R1)—, —O—, —S(O)—, —S(O)2—, —CO—, —CH(R1)— or a bond, ring B represents an optionally substituted imidazole ring, wherein a substituent which the optionally substituted imidazole ring represented by ring B may have may be taken together with R1 to form an optionally substituted ring, and a represents 0, 1 or 2.
Owner:TAKEDA PHARMA CO LTD

Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases

Flavivirus, rhabdovirus and paramyxovirus infections may be treated by administering an inhibitor of the enzyme dihydroorotate dehydrogenase such as 6-fluoro-2-(2′-fluoro-1,1′-biphenyl-4-yl)-3-methyl-4-quinolinearcarboxylic acid sodium salt (Brequinar). A synergistic effect can be obtained if an interferon such as interferon α2, interferon α8 or interferon β, or an inhibitor of a second enzyme selected from inosine monophosphate dehydrogenase, guanosine monophosphate synthetase, cytidine triphosphate synthetase and S-adenosylhomocysteine hydrolase, is also administered.
Owner:INST OF MOLECULAR & CELL BIOLOGY

Methods for treating urinary incontinence and other disorders using trospium

InactiveUS20050043342A1Potent activityAvoiding concomitant liabilityBiocideAnimal repellantsDiseaseSide effect
Methods are disclosed using Trospium Chloride, an antimuscarinic smooth muscle relaxant, for the treatment of urinary incontinence, and other disorders, while avoiding the concomitant liability of adverse side effects associated with other antimuscarinic drugs.
Owner:BRIDGE PHARMA INC

Manufacturing process of glucosyltransferase inhibitors from cacao bean husk

This invention relates to a process for manufacturing a fraction of cacao bean husk having an inhibitory activity against glucosyltransferase in the prevention of tooth decay and more particularly, to the process for manufacturing a fraction of cacao bean husk having more potent activity against glucosyltransferase in the prevention of tooth decay, while providing an economically feasible recovery process designed to treat enormous wastes of cacao bean husk, wherein it comprises the steps in which: an extract of cacao bean husk, which has already proven to exhibit an excellent inhibitory activity against glucosyltransferase, is formed from cacao bean husk; and, the extract is again added to an adsorption resin and fractioned by 50% thanol aqueous solution.
Owner:LOTTE CONFECTIONERY

Methods for treating smooth muscle contractions using trospium

InactiveUS20060293356A1Potent activitySafely be used as treatmentBiocideMuscular disorderDiseaseSide effect
Methods are disclosed using trospium, an antimuscarinic smooth muscle relaxant, for the treatment of smooth muscle disorders, while avoiding the concomitant liability of adverse side effects associated with conventional antimuscarinic treatment.
Owner:BRIDGE PHARMA INC

Formulation comprising antibacterial substance and antiulcer substance

The present invention includes a formulation which comprises an antibacterial substance and an antiulcer substance, wherein at least either of them is formulated into a gastrointestinal mucosa-adherent solid preparation. The formulation of the present invention shows long retention time in the gastrointestinal tract because of adhesion to the gastrointestinal tract mucosa, synergetically enhances the pharmaceutical effects of an antibacterial substance, specially antibiotic against Helicobacter pylori (HP) and an antiulcer substance, with very low doses of active ingredients, particularly the anti-HP antibiotic with low prevalence of side effects. The present agent is useful as an antiulcer agent, showing potent anti-HP activity.
Owner:AKIYAMA YOHKO +3

Method for amplifying natural killer t cells

Human Valpha24<+> natural killer T cells are expanded by culturing a mononuclear cell fraction obtainable from human peripheral blood in which hemopoietic stem cells are mobilized by granulocyte colony-stimulating factor, in the presence of a cytokine, such as interleukin 2, effecting proliferation and / or activation of lymphocytes and alpha-glycosylceramide. A cell fraction comprising human Valpha24<+> natural killer T cells expanded by the method, is useful as a cancer-treating agent.
Owner:KIRIN BREWERY CO LTD

Long-acting injectable formulations comprising an isoxazoline active agent, methods and uses therof

This invention relates to long-acting injectable formulations for combating parasites in animals, comprising at least one isoxazoline active agent, a poloxamer, and a co-solvent. This invention also provides for improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the long-acting injectable formulations of the invention to the animal in need thereof.
Owner:BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC

Substituted Pyran Derivatives

ActiveUS20140309427A1Potent activityOrganic chemistryMonoamine transportBiochemistry
Certain 3,6-disubstituted and 2, 4, 5-trisubstituted pyran derivatives that exhibit potent activity on monoamine transport systems are provided. The 3, 6 and 2, 4, 5 pyrans are useful in probing the effects of their binding to monoamine transporter systems and the corresponding relationships to various afflictions affecting the CNS, or as a treatment for various CNS-related disorders in which the monoamine transport and related systems are implicated.
Owner:WAYNE STATE UNIV

North-2'deoxy -methanocarbathymidines as antiviral agents for treatment of kaposi's sarcoma-associated herpes virus

A method for the prevention or treatment of Kaposi's sarcoma or Kaposi's sarcoma-associated herpes virus infection by administering an effective amount of a cyclopropanated carbocyclic 2′-deoxynucleoside to an individual in need thereof is provided.
Owner:US DEPT OF HEALTH & HUMAN SERVICES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products